Day One Biopharmaceuticals, Inc. (DAWN)

Market Cap	881.78M
Revenue (ttm)	131.16M
Net Income (ttm)	-95.50M
Shares Out	101.35M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	913,263
Open	8.73
Previous Close	8.79
Day's Range	8.34 - 8.85
52-Week Range	7.88 - 18.07
Beta	-1.39
Analysts	Strong Buy
Price Target	34.57 (+297.36%)
Earnings Date	May 5, 2025

About DAWN

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2021
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: DAWN
• Website: https://dayonebio.com

Analyst Forecast

According to 7 analysts, the average rating for DAWN stock is "Strong Buy." The 12-month stock price forecast is $34.57, which is an increase of 297.36% from the latest price.

Price Target

$34.57

(297.36% upside)

Analyst Consensus: Strong Buy